Fig. 2: Prospective epigenetic oncogenes and tumour suppressors exhibit clinical relevance in HCC patients. | Oncogenesis

Fig. 2: Prospective epigenetic oncogenes and tumour suppressors exhibit clinical relevance in HCC patients.

From: The role of histone demethylase PHF2 as a tumour suppressor in hepatocellular carcinoma by regulating SRXN1

Fig. 2

A Relative expression of prospective epigenetic oncogenes and tumour suppressors in normal tissues (n = 50) and HCC tumours (n = 374) from the GDC TCGA-LIHC patient cohort and corresponding Kaplan-Meier survival curves for HCC tumours when stratified according to the expression levels of the corresponding genes. Unpaired t-tests with and without Welch’s correction, where appropriate, were performed (n.s. not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Survival analyses were performed using the Log-rank (Mantel-Cox) test. B Differential expression of SUPT7L, SMARCC1 and PHF2 in paired normal tissues (blue) and tumours (red) from the GDC TCGA-LIHC patient cohort (n = 50). Paired t-tests were performed (***p < 0.001; ****p < 0.0001). Transcript expression values (log2(FPKM-UQ + 1)) from the TCGA were normalised by z-score transformation using the cohort mean and standard deviation prior to downstream analyses.

Back to article page